



APPOINTMENT OF GROUP CHIEF FINANCIAL OFFICER

For Immediate Release:

October 2016

- **Mr Peter Harding-Smith, B Bus, CA appointed Group Chief Financial Officer and Company Secretary of Anteo Diagnostics Limited and its Subsidiaries**
- **Strong experience in financial management and investor relations in ASX listed companies**

Anteo Diagnostics Limited (ASX:ADO) announces the appointment of Mr Peter Harding-Smith to the role of Group Chief Financial Officer for the Anteo Group.

Mr Harding-Smith brings a wealth of financial, governance and company secretarial experience to the Anteo Group. He is a Chartered Accountant, a Fellow of the Governance Institute of Australia and has over 10 years' experience in ASX listed companies as Chief Financial Officer and Company Secretary.

Mr Harding-Smith will take over from Mr Richard Martin, who will remain as a Non-executive Director and Chair of the Audit Committee, and will be available to assist Mr Harding-Smith to ensure a smooth transition. The Board wishes to thank Mr. Martin for long and dedicated service as CFO and look forward to his continuing financial leadership on the Board of Directors.

Dr Jef Vangenechten said: "Peter joins Anteo at an important time. Peter's history of delivery will be invaluable in coordinating our efforts to realise the potential that Anteo technology offers. With the recent appointment of Mrs Tamara Mills as COO of Brisbane operations and now Mr Peter Harding-Smith as Group CFO, I believe Anteo has selected a high calibre team to transform our vision into reality, attract more interest in the investor market, and yield deserving results for shareholders."

Mr Peter Harding-Smith said: "I'm keen to get started at Anteo, where the opportunities for growth in a global business are very exciting. I'm looking forward to delivering on Anteo's strategy and growing solid market support for our business."

The Board has agreed to issue Mr Harding-Smith's with 2,000,000 options to acquire Fully Paid Ordinary Shares as part of his package. These options will have an exercise period of 4 years, with an exercise price based on 150% of the 10 day VWAP on the issue date and will vest one year from the date of issue.



anteo diagnostics

About Anteo Diagnostics Limited

Anteo Diagnostics Limited (ASX: ADO) is a global nanochemistry technology company, developing and commercializing products for the life sciences and clinical diagnostics, medical devices, and energy.

The Anteo Group owns a patented nanochemistry technology which unites the strength and stability of covalent bindings with the gentleness of passive bindings through multi-point chelation. Used as a binder, coating or primer, Anteo's reagents target high-value commercial applications in protein binding and anti-body coupling (e.g point of care devices), primers for in-vivo medical devices and medical drug delivery, and coatings in batteries.

Anteo recently acquired DIAsource ImmunoAssays (Belgium). DIAsource has a strong track-record of continuing growth in revenue, EBITDA and positive cash flow and provides a profitable platform to roll out Anteo technology for life science and diagnostics.

For more information, please visit www.anteodx.com